Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-Hodgkin lymphoma, a life-threatening blood cancer.